Natera president sells $4.1 million in inventory

AUSTIN, Texas—Solomon Moshkevich, President of Scientific Diagnostics at Natera, Inc. (NASDAQ:NTRA), just lately bought a good portion of his holdings within the firm. The sale comes as Natera’s inventory has proven exceptional energy, with a 159% return over the previous yr and the corporate attaining a market capitalization of $22.12 billion. In response to a submitting with the Securities and Trade Fee, Moshkevich bought a complete of 24,861 shares of Natera’s frequent inventory on January 22, 2025, producing roughly $4.1 million. These transactions occurred at costs starting from $164.95 to $171.95 per share.

Following these gross sales, Moshkevich retains possession of 140,684 shares within the firm. In response to the submitting, the gross sales have been performed to fulfill tax withholding obligations associated to the vesting of restricted inventory models, in accordance with a pre-established buying and selling plan. InvestingPro evaluation reveals Natera maintains a powerful monetary place with a ‘GOOD’ well being rating and sturdy liquidity, as evidenced by a present ratio of 4.39. For deeper insights into insider buying and selling patterns and complete monetary evaluation, buyers can entry the detailed Professional Analysis Report, out there solely on InvestingPro.

In different current information, Natera Inc . has been making waves within the business. Barclays (LON:BARC) just lately upgraded the corporate’s inventory score to Chubby with a $200 goal, citing its enlargement into new markets and spectacular income development of practically 55% over the past twelve months. Analyst Luke Sergott highlighted Natera’s evolution from its authentic non-NGS-based NIPT focus to changing into a number one participant within the NIPT market and its extension into NGS-based Oncology and Organ Well being testing.

Natera has additionally expanded its patent infringement litigation in opposition to NeoGenomics (NASDAQ:NEO) involving the RaDaR assay. Regardless of dealing with a setback in a false promoting lawsuit in opposition to Guardant Well being (NASDAQ:GH), Natera plans to request the court docket to overturn the ruling. Moreover, an settlement with Dr. Rabinowitz, the Government Chairman, has been amended for him to proceed his function beneath sure circumstances.

TD Cowen has reiterated a Purchase score on Natera shares, elevating the value goal from $175 to $195, reflecting confidence within the firm’s future efficiency. Equally, Baird and Jefferies additionally maintained favorable rankings on Natera’s inventory and raised their value targets.

Lastly, Natera reported a document Q3 income of $439.8 million, marking a 64% enhance from the earlier yr, and performed 137,000 oncology exams. These current developments present buyers with an perception into Natera’s present standing and future prospects.

This text was generated with the assist of AI and reviewed by an editor. For extra info see our T&C.